Humana (NYSE:HUM)‘s stock had its “hold” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. They presently have a $230.00 target price on the insurance provider’s stock. Cantor Fitzgerald’s price target indicates a potential downside of 9.21% from the company’s current price.

A number of other brokerages have also commented on HUM. Deutsche Bank boosted their price objective on Humana from $234.00 to $243.00 and gave the stock a “hold” rating in a report on Monday, August 7th. UBS reissued a “neutral” rating and set a $250.00 price objective (up from $237.00) on shares of Humana in a report on Wednesday, August 9th. BidaskClub raised Humana from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Morgan Stanley boosted their price objective on Humana from $269.00 to $276.00 and gave the stock an “overweight” rating in a report on Thursday, August 17th. Finally, ValuEngine raised Humana from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Twelve research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $255.80.

Humana (NYSE HUM) traded up $1.06 during mid-day trading on Tuesday, reaching $253.34. The company had a trading volume of 927,700 shares, compared to its average volume of 1,384,502. Humana has a fifty-two week low of $186.25 and a fifty-two week high of $264.56. The company has a current ratio of 1.61, a quick ratio of 1.61 and a debt-to-equity ratio of 0.35. The firm has a market cap of $36,040.74, a P/E ratio of 21.53, a P/E/G ratio of 1.73 and a beta of 0.88.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share for the quarter, topping analysts’ consensus estimates of $3.27 by $0.12. Humana had a return on equity of 15.99% and a net margin of 3.49%. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. During the same period in the prior year, the business earned $3.18 EPS. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. equities analysts predict that Humana will post 11.63 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. WFG Advisors LP raised its position in shares of Humana by 4.5% in the second quarter. WFG Advisors LP now owns 469 shares of the insurance provider’s stock worth $113,000 after buying an additional 20 shares in the last quarter. Fieldpoint Private Securities LLC purchased a new stake in Humana during the third quarter valued at about $115,000. Acrospire Investment Management LLC purchased a new stake in Humana during the second quarter valued at about $120,000. Northwestern Mutual Wealth Management Co. raised its position in Humana by 139.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 558 shares of the insurance provider’s stock valued at $134,000 after purchasing an additional 325 shares in the last quarter. Finally, Fiduciary Trust Co. bought a new position in shares of Humana during the second quarter valued at about $135,000. 94.19% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Humana (HUM) Given Hold Rating at Cantor Fitzgerald” was published by American Banking News and is owned by of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/06/humana-hum-given-hold-rating-at-cantor-fitzgerald.html.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.